prasugrel-hydrochloride and Carcinoma--Squamous-Cell

Patients are generally required to stop antiplatelet therapy prior to elective invasive procedures. Some patients receive dual antiplatelet therapy for recent vascular procedures such as drug-eluting coronary stenting, and early discontinuation of antiplatelet agents could lead to a significant risk of stent thrombosis. Most bronchoscopic procedures are performed on patients using Aspirin but not on those using Clopidogrel or Prasugrel. In this report, we describe a unique case of a patient with a recent placement of drug-eluting stents, who required endobronchial biopsies for evaluation of lung cancer recurrence. The procedure was performed successfully and safely with no complications.

Topics: Angioplasty, Balloon, Coronary; Aspirin; Biopsy, Needle; Bronchoscopy; Carcinoma, Squamous Cell; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Recurrence, Local; Patient Safety; Platelet Aggregation Inhibitors; Pneumonectomy; Prasugrel Hydrochloride; Radiography; Risk Assessment; Treatment Outcome